Study details
Enrolling now
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
University of Washington
NCT IDNCT05822609ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 2.2 years
Ages
18+
Locations
3 sites in CO, WA
What this study is about
Researchers are testing whether semaglutide helps with kidney health and function in people with type 1 diabetes. The trial also looks at how semaglutide affects blood sugar levels and safety in this population.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Semaglutide
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
semaglutide (GLP-1 agonist; stimulates insulin release)
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Change in estimated glomerular filtration rate
Body systems
Endocrinology, Renal